OptiBiotix Health PLC Strategic partnership with Bened Biomedical (5525Q)
13 September 2017 - 4:00PM
UK Regulatory
TIDMOPTI
RNS Number : 5525Q
OptiBiotix Health PLC
13 September 2017
OptiBiotix Health plc
("OptiBiotix" or "the Company")
Strategic partnership with Bened Biomedical
OptiBiotix Health Plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol and
diabetes, has signed a Memorandum of Understanding ("MoU") with
Bened Biomedical Ltd., Taiwan ("Bened"). The MoU sets the framework
for a strategic partnership to explore licensing and sales
opportunities and the potential of combining relevant assets, over
the next 12 months.
Bened Biomedical Co., Ltd., was founded in 2015 as a spin off
from National Yang-Ming University ("NYMU") by Professor Tsai,
Ying-Chieh. Bened is a leading probiotic research and marketing
companies in Asia developing microbiome based products for
neuropsychological, allergic, immunological, metabolic and
aging-related disorders. In the past two years, its flagship
psychobiotic PS128(R) products which help improve mental and
emotional health, have been sold through both on-line and off-line
channels in more than ten countries, generating revenues in the
excess of US$2m.
The MoU provides a 12 month period to explore opportunities
relating to OptiBiotix's cholesterol and blood pressure reducing
LP(LDL) (R) strain and Bened's PS128(R) , a psychobiotic that has
shown encouraging results in reducing anxiety and depression in
animal studies.
This agreement includes:-
-- The potential for Bened to commercialise OptiBiotix's LP(LDL)
(R) strain in Taiwan, Japan, Korea, and South East Asia
-- The potential for OptiBiotix to commercialise Bened's PS128 strain in Europe and the USA
-- The possibility of combining relevant assets to broaden the
commercial offering and global reach
For OptiBiotix this means:
-- Widening OptiBiotix's probiotic portfolio into the area of psychobiotics
-- Entering into the area of the "Microbiota-Gut-Brain Axis"
where mounting evidence suggests that the microbiome helps shape
neural development, brain biochemistry and behaviour
-- Opening commercial routes into Taiwan, Japan, Korea and SE
Asia for the Company's cholesterol and blood pressure reducing
LP(LDL) (R) strain
-- Gaining access to territories in the Asia Pacific region with
a total probiotic retail value of $16.1 billion, of which
supplements are $700 million. Japan being the third largest market
for probiotic supplements with a predicted 8% growth by 2021 and
the Taiwanese markets predicted a 27% growth by 2021
The two parties aim to enter definitive legal agreement on
commercial and financial terms during the 12 month period. This is
expected to create mutual value through royalty or asset payments.
More information about the specific agreement will be provided in
due course.
Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING
THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June
2017).
Stephen O'Hara, Chief Executive Officer of OptiBiotix, said: "We
are pleased to announce this strategic partnership with Bened
Biomedical and see a strong rationale for both companies to work
together based on a complementary understanding of the science in
different application areas of the microbiome. We are excited by
recent advances in psychobiotics which have the potential to
address a range of mental and emotional health issues such as
anxiety, depression, autism and Parkinson's. We strongly believe
Bened's scientific and commercial capabilities in psychobiotics
creates potential for OptiBiotix to bring new products to new
markets and extend both our product offering and global reach in
the microbiome field to bring better science and better health to
all."
Frankie Cheng, Chief Executive Officer of Bened Biomedical,
said: "OptiBiotix operates in a very exciting and progressive area
that has the potential to bring real health benefits. It has
exciting products with strong science and clinical studies which we
believe can be commercialised successfully through our distribution
capability. We see mutual benefit in OptiBiotix's commercial
advances in Europe and US as a way to bring our PS128(R) product to
a wider audience."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Tony Quirke / Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLTMATMBJBBJR
(END) Dow Jones Newswires
September 13, 2017 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024